Inflarx N.V. (IFRX) has released an update.
InflaRx N.V., a biotech firm targeting anti-inflammatory therapeutics, announced plans to focus on immuno-dermatology with its drugs vilobelimab and INF904, targeting conditions like CSU and HS. A Phase IIa study for INF904 is slated for late 2024, with results expected in 2025, while ongoing Phase III trials for vilobelimab in PG are also progressing. The company’s strong cash position is expected to fund operations into 2026, as they explore partnership options to expand INF904’s potential in various medical fields.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
